




RealRate

MEDICINAL PRODUCTS 2017

Celldex Therapeutics Inc.
Rank 21 of 44



RealRate

The First AI Rating Agency

www.realrate.ai



MEDICINAL PRODUCTS 2017

Celldex Therapeutics Inc.
Rank 21 of 44



The relative strengths and weaknesses of Celldex Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Celldex Therapeutics Inc. compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Celldex Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 38%, being 85% points above the market average of -47%.

Input Variable	Value in 1000 USD
Assets, Current	195,569
Assets, Non-Current	2,134
General and Administrative Expense	35,979
Goodwill	172,463
Liabilities, Current	35,223
Liabilities, Non-Current	82,704
Other Assets	0
Other Compr. Net Income	4,620
Other Expenses	997
Other Liabilities	0
Other Net Income	0
Other Revenues	6,786
Property, Plant and Equipment, Net	13,192
Research and Development	102,726

Output Variable	Value in 1000 USD
Liabilities	117,927
Assets	383,358
Expenses	139,702
Revenues	6,786
Stockholders Equity	265,431
Net Income	-132,916
Comprehensive Net Income	-130,606
Economic Capital Ratio	38%